Track topics on Twitter Track topics that are important to you
The purpose of the study is to look at the levels of three HIV medications darunavir, ritonavir and atazanavir in the blood after the drug intake has been stopped in order to understand how long these drugs persist in blood for. The study will specifically look at these three drugs blood levels after taking them for 10 days everyday.
The main objective is to provide information on the potential safety (in terms of preventing virological failure and the development of resistance)of delaying drug doses occasionally by providing information on the decline in drug concentration after dosing has stopped.
The long term use of and success of antiretroviral therapy (ART) is constrained by many factors including poor adherence and drug intolerance. Poor adherence (missing ART doses) may lead to the achievement of sub therapeutic drug plasma concentrations and virological failure. This could also be complicated by the development of resistance to ART which compromises future therapeutic options because of cross resistance within antiretroviral drug classes.
In medicine, successful adherence is supposed to mean taking at least 80% of doses. This is a concept, which has been inherited from the antihypertensive literature and anti-infective prescribing for therapeutic areas which from that of HIV prescribing in fundamental principles. The current absence of a curative therapy for HIV infection, means that in order to be effective, suppressive therapies need to be taken on an indefinite lifelong basis. The capacity for development of resistance of the virus means that successful adherence equates to a much higher rate of adherence than 80%. Moreover, in HIV therapy, successful adherence also means attention to a maximum interval between doses as well as dietary restriction at the time of dose intake.
Ideally, to guarantee long-term virological response, HIV-infected patients should take their ART every day at the same time. However, ART is for life and doses can be forgotten or delayed.
A recent survey confirmed the reasons why people miss their antiretroviral doses: they forget, they fall asleep, they are too busy, they are depressed, they are away from home, and their medicines make them sick (Mascolini www.thebody.com 2003).
Drug persistence (the presence of drug at a detectable level high enough to work) in plasma mainly depends on the half-life. Long half-life antiretroviral agents may allow for forgotten doses, if they are able to delay the decline of the drug level to sub-therapeutic concentrations for long enough for the patient to remember to take the drug. Boosted PI are characterized by different half lives, and therefore different abilities to persist in plasma.
Unfortunately, data on drug persistence in plasma are limited and whether drug doses can be forgotten and dosing delayed is unknown.
Therefore, the main objective of this study is to provide information on the potential safety (in terms of preventing virological failure and the development of resistance) of delaying drug doses occasionally by providing information on the decline in drug concentration after dosing has stopped.
Rationale for pharmacogenomic analysis
Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multi antiretroviral drug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged.
From a public health perspective, as antiretroviral medications become increasingly available to racially and ethnically diverse populations worldwide, understanding the genetic structures of each population may allow us to anticipate the impact of adverse responses, even in groups that were not represented in drug registration trials.
The existing literature on pharmacogenetic determinants of antiretroviral drug exposure, drug toxicity, as well as genetic markers associated with the rate of disease progression underline the recent advances which occurred in the past few years.
However, it is expected that larger-scale comprehensive genome approaches will profoundly change the landscape of knowledge in the future. Additional studies are needed to assess the implications for long-term responses to antiretroviral agents.
For this reason we plan to collect a single blood sample from each participant in our intensive pharmacokinetic studies, such as this one, in order to be able to investigate the association between genetic polymorphisms in drug disposition genes (such as those encoding for cytochrome P450 isoenzymes or transmembrane transporters) and drug exposure. A candidate gene approach will be utilised to examine loci of interest. This procedure will provide potentially important information on genetic influences on plasma drug concentrations and give insight into how to improve the management of HIV-infected patients by individualising therapy. These studies will not be powered for genetic associations but will enable us to build a data base of genotype-phenotype associations. Prospective genetic studies would need to be planned based on these preliminary data.
Control: Uncontrolled, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
darunavir/ritonavir then atazanavir/ritonavir
St Stephen's Centre
St Stephens Aids Trust
Published on BioPortfolio: 2014-08-27T03:15:42-0400
The purpose of this clinical research study is to assess the effect of omeprazole at 20 mg on the pharmacokinetics of atazanavir administered as atazanavir with ritonavir relative to ataza...
The primary objective of this study is to continue to provide Darunavir (DRV) to pediatric patients who previously received DRV in any of three pediatric clinical studies sponsored by Tibo...
The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir, identifying one or more dosing regimens of atazanavir/ritonavir/tenofovir when dosed with famot...
The purpose of this study is to characterise the pharmacokinetic profiles of non-nucleoside analog reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), and the influenc...
The purpose of this clinical research study is to assess the effect of Famotidine given twice daily on Atazanavir administered with Ritonavir in HIV-Infected subjects.
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
In the ANRS 165 DARULIGHT study (NCT02384967) carried out in HIV-infected patients, the use of a darunavir/ritonavir-containing regimen with a switch to a reduced dose of darunavir maintained virologi...
Dual therapy based on dolutegravir and ritonavir-boosted darunavir (DTG/DRV/r) is a combination of well-known drugs with a high genetic barrier to HIV resistance.
Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in pa...
To evaluate changes in pro-atherosclerotic biomarkers and endothelial function in patients initiating two different PI-based regimens as part of ART.
Drug combination nanoparticles (DcNP) administered subcutaneously represent a potential long-acting lymphatic-targeting treatment for HIV-infection. The DcNP containing lopinavir-ritonavir-tenofovir, ...
An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV.
An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.
An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS.
An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.
Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...